Aradigm Corp.'s common stock will be suspended from Nasdaq trading on Sept. 14.
The delisting comes after Aradigm failed to regain compliance with the exchange's $35 million minimum market value of listed securities. Aradigm received the noncompliance notice in March, and had until Sept. 4 to regain compliance.
Aradigm may request a hearing to appeal the delisting, and stay the suspension. The company said it is evaluating available options to regain compliance.
Hayward, Calif.-based Aradigm develops drugs for the prevention and treatment of severe respiratory diseases.